Nkarta to Participate at Upcoming Investor Conferences
Thursday, April 13, 2023 1 min read
Key Takeaway: Nkarta, Inc. announced its participation in two upcoming investor conferences, namely the 22nd Annual Needham Virtual Healthcare Conference and the Canaccord Genuity Horizons in Oncology Virtual Conference. At these events, Nkarta will engage with potential investors through a fireside chat and a panel discussion. The company specializes in developing engineered natural killer (NK) cell therapies for cancer, highlighting its commitment to advancing innovative cancer treatments. The investor conferences will be accessible via a webcast, with replays available on Nkarta's website.
Market Sentiment Analysis
POSITIVE FACTORS
Nkarta is actively participating in notable investor conferences, indicating investor engagement.
The company is advancing innovative NK cell therapies aimed at cancer treatment.
Nkarta's use of CRISPR-based technologies enhances its therapeutic prospects.
Full Press Release Details
SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at two upcoming investor conferences:
22nd Annual Needham Virtual Healthcare Conference
3:00 p.m. ET – fireside chat
Canaccord Genuity Horizons in Oncology Virtual Conference
3:00 p.m. ET – panel discussion
A simultaneous webcast of each event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for patients with cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Frequently Asked Questions
What is Nkarta, Inc. focused on developing?
Nkarta, Inc. is developing engineered natural killer cell therapies for cancer.
When is Nkarta's participation in the Needham Conference?
Nkarta will participate in the Needham Conference on April 12, 2023, at 3:00 p.m. ET.
Where can I watch Nkarta’s conference presentations?
Webcasts of Nkarta’s conference presentations will be available on their website.
What technologies does Nkarta use in its therapies?
Nkarta combines cell expansion, cryopreservation, and CRISPR technologies.
How long will the conference replays be available?
The replays of the conferences will be archived for approximately 90 days.